Supplementary Table 1. Patient characteristics of the pooled data set in relation to MMR and *BRAF* mutation status

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | | | | | | | | | | | | | | | | | |
|  | dMMR | | pMMR | | | | *BRAF*MT | | | | *BRAF*WT | | | |
|  | *BRAF*MT | *BRAF*WT | *BRAF*MT | | *BRAF*WT | | dMMR | | pMMR | | dMMR | | pMMR | |
|  | n=53 | n=100 | n=211\* | | n=2713 | | n=53 | | n=211\* | | n=100 | | n=2713 | |
| Sex |  |  |  | |  | |  | |  | |  | |  | |
| male | 25 (47%) | 66 (66%) | 119 (56%) | | 1778 (65%) | | 25 (47%) | | 119 (56%) | | 66 (66%) | | 1778 (65%) | |
| female | 28 (53%) | 33 (33%) | 92 (44%) | | 918 (34%) | | 28 (53%) | | 92 (44%) | | 33 (33%) | | 918 (34%) | |
| missing | - | 1 (1%) | - | | 17 (1%) | | - | | - | | 1 (1%) | | 17 (1%) | |
| Age\*\* |  |  |  | |  | |  | |  | |  | |  | |
| median | 69.0 | 63.1 | 65.0 | | 63.8 | | 69.0 | | 65.0 | | 63.1 | | 63.8 | |
| Localization of the primary tumor |  |  |  | |  | |  | |  | |  | |  | |
| colon | 47 (88%) | 65 (65%) | 158 (75%) | | 1427 (52%) | | 47 (88%) | | 158 (75%) | | 65 (65%) | | 1427 (52%) | |
| rectosigmoid | 1 (2%) | 6 (6%) | 21 (10%) | | 336 (12%) | | 1 (2%) | | 21 (10%) | | 6 (6%) | | 336 (12%) | |
| rectum | 1 (2%) | 25 (25%) | 29 (14%) | | 867 (32%) | | 1 (2%) | | 29 (14%) | | 25 (25%) | | 867 (32%) | |
| multiple tumor | - | - | - | | 3 (1%) | | - | | - | | - | | 3 (1%) | |
| missing | 4 (8%) | 4 (4%) | 3 (1%) | | 80 (3%) | | 4 (8%) | | 3 (1%) | | 4 (4%) | | 80 (3%) | |
| Performance status |  |  |  | |  | |  | |  | |  | |  | |
| PS0 | 26 (49%) | 45 (45%) | 105 (50%) | | 1347 (50%) | | 26 (49%) | | 105 (50%) | | 45 (45%) | | 1347 (50%) | |
| PS1 | 22 (42%) | 50 (50%) | 91 (43%) | | 1176 (43%) | | 22 (42%) | | 91 (43%) | | 50 (50%) | | 1176 (43%) | |
| PS2 | 5 (9%) | 4 (4%) | 15 (7%) | | 145 (6%) | | 5 (9%) | | 15 (7%) | | 4 (4%) | | 145 (6%) | |
| missing | - | 1 (1%) | - | | 18 (1%) | | - | | - | | 1 (1%) | | 18 (1%) | |
| Metastatic sites involved |  |  |  | |  | |  | |  | |  | |  | |
| one | 27 (51%) | 32 (32%) | 76 (36%) | | 1087 (40%) | | 27 (51%) | | 76 (36%) | | 32 (32%) | | 1087 (40%) | |
| ≥ two | 25 (47%) | 64 (64%) | 133 (63%) | | 1580 (58%) | | 25 (47%) | | 133 (63%) | | 64 (64%) | | 1580 (58%) | |
| missing | 1 (2%) | 4 (4%) | 2 (1%) | | 46 (2%) | | 1 (2%) | | 2 (1%) | | 4 (4%) | | 46 (2%) | |
|  | | | | | | | | | | | | | | | | | | |
| Abbreviations: wt = wild-type tumors, mt = mutant tumors, pMMR = proficient mismatch repair system, dMMR = deficient mismatch repair system | |  |  |  | |  | |  | |  | |  | |  | |  |  |  |
| \* + 14 patients with a non-V600E *BRAF* mutation | | | | | | | | | | | | | | | |  |  |  |  |  |  |  |  |
| \*\* the COIN patients are excluded, due to missing data | |  |  |  | |  | |  | |  | |  | |  | |  |  |  |
|  | | |  |  | |  | |  | |  | |  | |  | |  |  |  |